Les inhibiteurs mTOR : nouvel outil thérapeutique dans la prise en charge de la Sclérose Tubéreuse de Bourneville. Expérience de l’équipe multidisciplinaire des Cliniques universitaires Saint-Luc

Dekeuleneer, Valérie;Ho, Thien Anh;Van Rijckevorsel, Germaine;Sznajer, Yves;Pirson, Yves;et.al.
(2015) Louvain médical — Vol. 134, n° 10, p. 537-546 (2015)

Files

2015_Dekeuleneer_LM_13410_537-546.pdf
  • Restricted Access
  • Adobe PDF
  • 436.96 KB
Request a copy

Details

Authors
Show more
Abstract
(en) [mtoR inhibitors: a new treatment option in the management of tuberous sclerosis complex. experience of the multidisciplinary team at Saint-Luc University Clinics] Tuberous sclerosis complex (TSC) is a multisystemic disorder requiring a multidisciplinary approach. Until recently, only symptomatic treatments were available. Over the last years, however, the treatment of TSC has been revolutionized by the proven usefulness and efficacy of mTOR inhibitors offering a multisystemic and targeted approach. A Center for congenital neurocutaneous diseases has recently been created at the Saint-luc University Clinics, proposing multidisciplinary consultations, especially for TSC patients.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Dekeuleneer, V., Ho, T. A., Van Rijckevorsel, G., Sznajer, Y., Nassogne, M.-C., Godefroid, N., Derouaux, A.-S., & Pirson, Y. (2015). Les inhibiteurs mTOR : nouvel outil thérapeutique dans la prise en charge de la Sclérose Tubéreuse de Bourneville. Expérience de l’équipe multidisciplinaire des Cliniques universitaires Saint-Luc. Louvain médical, 134(10), 537-546. https://hdl.handle.net/2078.5/95485 (Original work published 2015)